Citius Oncology, Inc. (CTOR) shareholders
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.52−0.03 (-5.87%)
Close on Nov 12, 2026Market cap $48.56MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
15.2%
14M of 93M shares
Institutional holders
19
7 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | 66,049,615 | 71.00% | 13D (active) amendment | May 15, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 9,353,553 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.79%) | 7,675,911 | 9.79% | 13G (passive) | Sep 30, 2025 |
| Mizuho Financial Group, Inc. | 522,030 | 5.84% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTOR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 8,705,589 | 9.36% | $5.66M | −483,266 | 0.07% |
| Bank Of America Corp /De/ | 3,835,160 | 4.12% | $2.49M | – | 0.00% |
| Vanguard Capital Management LLC | 546,325 | 0.59% | $355.11K | +11,501 | 0.00% |
| UBS Group AG | 334,619 | 0.36% | $217.50K | +297,779 | 0.00% |
| Geode Capital Management, LLC | 245,407 | 0.26% | $159.54K | −19,326 | 0.00% |
| Vanguard Fiduciary Trust Co | 121,910 | 0.13% | $79.24K | – | 0.00% |
| IFP Advisors, Inc | 107,424 | 0.12% | $69.84K | – | 0.00% |
| Citadel Advisors LLC | 90,586 | 0.10% | $58.89K | New | 0.00% |
| Northern Trust Corp | 45,746 | 0.05% | $29.74K | – | 0.00% |
| State Street Corp | 42,900 | 0.05% | $27.89K | – | 0.00% |
| Virtu Financial LLC | 21,877 | 0.02% | $14.00K | New | 0.00% |
| XTX Topco Ltd | 20,638 | 0.02% | $13.42K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 13,816 | 0.01% | $8.98K | New | 0.00% |
| Arkadios Wealth Advisors | 11,666 | 0.01% | $7.58K | – | 0.00% |
| Osaic Holdings, Inc. | 1,000 | 0.00% | $650 | −9,125 | 0.00% |
| Wells Fargo & Company/Mn | 500 | 0.00% | $325 | New | 0.00% |
| Barclays PLC | 90 | 0.00% | $59 | New | 0.00% |
| Morgan Stanley | 23 | 0.00% | $15 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 19 | 14M | 15.2% | 7 / 2 | 3 / 2 | 0M | 1M |
| Q1 2026 | 14 | 14M | 15.3% | 3 / 7 | 1 / 6 | 8M | 0M |
| Q4 2025 | 18 | 7M | 7.4% | 6 / 5 | 4 / 4 | 1M | 2M |
| Q3 2025 | 16 | 8M | 9.0% | 10 / 3 | 2 / 1 | 8M | 0M |
| Q2 2025 | 7 | 0M | 0.2% | 2 / 3 | 1 / 1 | 0M | 0M |
| Q1 2025 | 6 | 0M | 0.1% | 0 / 2 | 1 / 5 | 0M | 0M |
| Q4 2024 | 11 | 0M | 0.2% | 5 / 2 | 1 / 1 | 0M | 0M |
| Q3 2024 | 7 | 0M | 0.0% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
8 funds held CTOR in Q1 2026, 74% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CTOR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 370,100 | 0.40% | $240.60K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 176,225 | 0.19% | $114.56K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 112,734 | 0.12% | $89.96K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 57,297 | 0.06% | $45.72K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 26,290 | 0.03% | $20.98K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 23,392 | 0.03% | $18.67K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | 1,700,000 | 1.83% | Nov 12, 2026 |
| Myron Z. Holubiak | Secretary, Director | 950,000 | 1.02% | Nov 12, 2026 |
| Jaime Bartushak | Chief Financial Officer | 825,000 | 0.89% | Nov 12, 2026 |
| Myron Czuczman | Chief Medical Officer | 825,000 | 0.89% | Nov 12, 2026 |
| Jonathan Peri | Director | 0 | – | Aug 14, 2026 |
| Dennis M. McGrath | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Robert Joseph Smith | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Suren G. Dutia | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Eugene Myron Holuka | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Carol Webb | Director | 300,000 | 0.32% | Dec 22, 2025 |
| Joel David Mayersohn | Director | 321,228 | 0.35% | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +850,000 | – | – | 850,000 |
| Leonard L. Mazur Chief Executive Officer, Director | Sep 19, 2025 | Award | +1,700,000 | – | – | 1,700,000 |
| Jaime Bartushak Chief Financial Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Robert Joseph Smith Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Dennis M. McGrath Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Carol Webb Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Suren G. Dutia Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Myron Czuczman Chief Medical Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Eugene Myron Holuka Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Joel David Mayersohn Director | Sep 19, 2025 | Award | +300,000 | – | – | 321,228 |
| Myron Czuczman Chief Medical Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Robert Joseph Smith Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Dennis M. McGrath Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Joel David Mayersohn Director | Sep 19, 2025 | Award | +300,000 | – | – | 321,228 |
| Leonard L. Mazur Chief Executive Officer, Director | Sep 19, 2025 | Award | +1,700,000 | – | – | 1,700,000 |
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +850,000 | – | – | 850,000 |
| Jaime Bartushak Chief Financial Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Carol Webb Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Suren G. Dutia Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Eugene Myron Holuka Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Carol Webb Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Robert Joseph Smith Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Leonard L. Mazur Chief Executive Officer, Director | Sep 19, 2025 | Award | +1,700,000 | – | – | 1,700,000 |
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +100,000 | – | – | 100,000 |
| Myron Z. Holubiak Secretary, Director | Sep 19, 2025 | Award | +850,000 | – | – | 850,000 |
| Eugene Myron Holuka Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Myron Czuczman Chief Medical Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Joel David Mayersohn Director | Sep 19, 2025 | Award | +300,000 | – | – | 321,228 |
| Suren G. Dutia Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Dennis M. McGrath Director | Sep 19, 2025 | Award | +300,000 | – | – | 300,000 |
| Jaime Bartushak Chief Financial Officer | Sep 19, 2025 | Award | +825,000 | – | – | 825,000 |
| Joel David Mayersohn Director | Jul 28, 2025 | Other | +21,228 | – | – | 21,228 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.97%
0M shares short
Days to cover
1.2
At 0M shares a day
Change since last report
-11.2%
From 0M shares
Short volume, 20 days
22.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Citius Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,458 shares on Oct 9, 2026 over the last 90 days.
See a number that looks wrong?